Table 3.

Published case reports of FSGS lesion post COVID vaccination

Study	Dormann et al.[14]	Klomjit et al.[13]	Present case report
Age/Sex	20 years/F	29 years/F	21 years/M
Vaccine type	BNT162b2 vaccine (Pfizer)	BNT162b2 vaccine (Pfizer)	AstraZeneca COVID-19 vaccine
Disease onset	Edema about 5 days after the first vaccination	Relapse of nephrotic syndrome 3 weeks post the second dose of vaccination	12 days after the first dose of vaccine
Presentation and laboratory features	New-onset NS, proteinuria: UPCR: 10.3 g/g, Alb 2: 120 mg/dl, Cr: 0.47 mg/dl, Chol: 566, LDL: 350, TG: 302 mg/dl, biopsy: FSGS	FSGS tip variant relapse. Was in remission for 24 months before relapse	New-onset NS, Urine protein 4+, 24-h urinary protein: 23.87 g, serum creatinine: 1.06 mg/dl, serum albumin: 0.9 g/dl, and total cholesterol: 324 mg/dl
		24-h urinary protein: 10 g/day, serum albumin: 2.2 g/dl. Serum creatinine normal (0.6-0.7 mg/dl)	Renal biospy: FSGS tip variant
Treatment and response	Prednisolone 60 mg/Taper, partial remission, after 10 days: proteinuria: UPCR 3.6 g/g, Alb 2 280 mg/dl; after 28 days: proteinuria: UPCR: 5.5 g/g; Alb 2: 340 mg/dl, Cr: normal, Chol: 450, TG: 230 mg/dl	High-dose steroid+tacrolimus 3.5 months of follow-up: 24-h urinary protein: 3.7 g/day, serum albumin: 3.2 g/dl (partial remission)	High-dose steroid×4 months, low-dose steroid+tacrolimus×7 months (continuing)
			High-dose steroid×3 months, low-dose steroid + tacrolimus× 7 months (continuing)
			Given Inj. rituximab 500 mg iv weekly× 4 doses (6 weeks back in the last week of November and first week of December 2021)

UPCR=Urine protein creatinine ratio, FSGS=Focal segmental glomerulosclerosis, TG=Triglyceride